Gentronix has announced an agreement with LSG Corporation to enable the introduction of the Greenscreen HC range of human cell-based genotoxicity assays across Japan.
The company said the agreement will allow scientists in Japan to accelerate the pace of drug discovery and development.
Greenscreen HC, also available with a standardised S9 metabolic activation protocol, identifies genotoxic compounds in early screening of drug candidates.
With a microplate format to enable high-throughput analysis, Greenscreen helps to remove the current bottlenecks commonly found in preclinical research and development.
